Literature DB >> 23417217

Market failure in the pharmaceutical industry and how it can be overcome: the CureShare mechanism.

Moshe Levy1, Adi Rizansky.   

Abstract

Allowing patients to take part in the initial investment for the development of cures for their illnesses can, under certain conditions, lead to the development of drugs that would have otherwise not been developed and to a dramatic welfare increase. We theoretically analyze these conditions. The suggested patient investment mechanism, which we call CureShare, does not involve any philanthropy or government subsidies. It is simply a way to overcome market failure. Based on empirical data, we estimate that applying this mechanism may save thousands of lives annually and may dramatically improve the quality of many others.

Entities:  

Mesh：

Year:  2013        PMID： 23417217     DOI： 10.1007/s10198-013-0461-8

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


  14 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

Review 2.  Can the pharmaceutical industry reduce attrition rates?

Authors:  Ismail Kola; John Landis
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

3.  The utility of health and wealth.

Authors:  Moshe Levy; Adi Rizansky Nir
Journal:  J Health Econ       Date:  2012-03-06       Impact factor: 3.883

4.  Cost of innovation in the pharmaceutical industry.

Authors:  J A DiMasi; R W Hansen; H G Grabowski; L Lasagna
Journal:  J Health Econ       Date:  1991-07       Impact factor: 3.883

5.  Time of diagnosis of chronic renal failure and assessment of quality of life in haemodialysis patients.

Authors:  R Sesso; M M Yoshihiro
Journal:  Nephrol Dial Transplant       Date:  1997-10       Impact factor: 5.992

6.  Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis.

Authors:  O Höie; L J Schouten; F L Wolters; I C Solberg; L Riis; I A Mouzas; P Politi; S Odes; E Langholz; M Vatn; R W Stockbrügger; B Moum
Journal:  Gut       Date:  2006-10-06       Impact factor: 23.059

7.  Alternative approaches to valuing intangible health losses: the evidence for multiple sclerosis.

Authors:  F A Sloan; W K Viscusi; H W Chesson; C J Conover; K Whetten-Goldstein
Journal:  J Health Econ       Date:  1998-08       Impact factor: 3.883

8.  Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients.

Authors:  N Milman; P Pedersen; T á Steig; K E Byg; N Graudal; K Fenger
Journal:  Ann Hematol       Date:  2001-10-11       Impact factor: 3.673

Review 9.  The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review.

Authors:  E V Loftus; P Schoenfeld; W J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2002-01       Impact factor: 8.171

10.  Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population.

Authors:  C Bryan; Y Howard; P Brennan; C Black; A Silman
Journal:  Br J Rheumatol       Date:  1996-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.